Issue Date: July 18, 2011
Amgen Licenses Micromet Technology
Amgen will pay Micromet $14 million up front to apply the Rockville, Md.-based biotech firm’s BiTE antibody technology against three solid-tumor targets. Amgen has the right to develop BiTE antibodies against two of the targets. It will cover all the program’s R&D costs, which the companies say could run up to $35 million. Micromet’s BiTE antibodies bind T cells to tumor cells, prompting cell death as well as the proliferation of more T cells at the tumor site.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society